1. ADALIMUMAB IN PATIENTS WITH REFRACTORY UVEITIS : study of 34 patients
P.Fanlo, H.Heras, P.Gonzalez, P.Ramos
Multidisciplinary Uveitis Unit.
Complejo Hospitalario de Navarra
Pamplona

2. Objetive:
Adalimumab is an anti-TNF-alpha agent, that has been used as out off label treatment in the case of refractory uveitis with good results.
Method:
We reviewed 34 patients diagnosed of uveitis belonging to the multidisciplinary unit of our center from 2010 to that received treatment with adalimumab. It was analyzed the following data: age, sex, diagnosis of uveitis , indication, initial dose and final dose, treatment with oral immunosuppressants and other biological drugs and reasons of suspension.

3. Results: Etiologies of uveitis 18 were women and main age was 43 years
In 30 patients was indicated as out off label treatment .
The initial dose was of 40 mg every 2 weeks except in 1 patient and the final dose in all cases was 40 each 2 weeks except in 3 patients.

4. Immunosupressive drugs
Results:
Immunosupressive drugs
3 patients had received prior treatment with infliximab and one also received rituximab.

5. Conclusion: Causes of suspension of adalimumab
The use of adalimumab is safe and effective for the treatment of refractory uveitis secondary mostly to spondyloarthropathies.
In addition can be the first choice therapeutic alternative to oral immunosuppressive drugs in uveitis with other etiologies.